CHAARTED and LATITUDE in Predicting Prognosis in Metastatic Hormone-Sensitive Prostate Carcinoma Comparison of Criteria
Halil Ibrahim Ellez1, Mehmet Uzun1, Huseyin Salih Semiz2, Murat Keser3, Olcun Umit Unal31Department of Internal Medicine, Division of Medical Oncology, Dokuz Eylul University, Izmir, Türkiye, 2Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Türkiye, 3Department of Medical Oncology, Tepecik Education and Research Hospital, Health Science University, Izmir, Türkiye
Objectives: Prostate carcinoma is the most common cancer in men and the second most common cancer causing death in the world. In this study, we will evaluate the CHAARTED and LATİTUDE classifications in predicting the prognosis in patients with mCSPC, investigate which group of patients are more reliable in predicting the prognosis according to these classifications, and examine which criteria show us the prognosis better in conflicting classifications. Methods: This retrospective, cross-sectional study included 296 patients who were treated for the diagnosis of prostate adenocarcinoma between January 1, 2010, and June 1, 2021. Patients were categorized as having high-volume disease (HVD) and low-volume disease (LVD) according to the definition used in the CHAARTED study, and HRD and low-risk disease (LRD) according to the LATITUDE trial. The patients were classified as low or high volume based on the CHAARTED study criteria and as low or high risk based on the LATITUDE trial criteria. Results: When two study criteria were matched, 74(%25) patients had cLaL, 46(%15.5) had cHaL, 10(%3.4) had cLaH and 166(%56.1) had cHaH. In addition, two study criteria were concordant %81.1 of patients and discordant %18.9 of patients. Median overall survival (OS) was 58 months (CI%95, 51.26-64.73) in the overall cohort (p<0.001). OS was found significantly lower on patients cHaH group (median: 41.06 months; CI%95, 34.88-47.25) compared to patients on cLaL (median:109.80 months; CI%95, 85.20-115.34)(p<0.001). Moreover, no significant differance was found when cLaH group (median:69 months.56;CI%95,29.02-110.10) compared with cHaL group. same results was found in progressionfree survival (PFS) and cancer spesific survival (CSS). Conclusion: Our study showed a lack of complete concordance between the CHAARTED and LATITUDE classifications. The need for new biomarkers and/or new classification criteria for these two groups still remains. Keywords: concordance,CHAARTED, LATITUDE, prostate cancer, prognosis
Cite This Article
Ellez H, Uzun M, Semiz H, Keser M, Unal O. CHAARTED and LATITUDE in Predicting Prognosis in Metastatic Hormone-Sensitive Prostate Carcinoma Comparison of Criteria. EJMI. 2023; 7(4): 346-352
Corresponding Author: Halil Ibrahim Ellez